Free Trial

AlloVir (ALVR) Competitors

AlloVir logo
$4.76 +0.31 (+6.97%)
As of 10/13/2025

ALVR vs. CTOR, PEPG, THTX, ANRO, CGEN, CCCC, ACOG, NVCT, IXHL, and GLSI

Should you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Citius Oncology (CTOR), PepGen (PEPG), Theratechnologies (THTX), Alto Neuroscience (ANRO), Compugen (CGEN), C4 Therapeutics (CCCC), Alpha Cognition (ACOG), Nuvectis Pharma (NVCT), Incannex Healthcare (IXHL), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry.

AlloVir vs. Its Competitors

Citius Oncology (NASDAQ:CTOR) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, Citius Oncology had 2 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Citius Oncology and 1 mentions for AlloVir. Citius Oncology's average media sentiment score of 0.31 beat AlloVir's score of 0.00 indicating that Citius Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Citius Oncology
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AlloVir
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 6.7% of Citius Oncology shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Citius Oncology currently has a consensus price target of $6.00, suggesting a potential upside of 252.94%. Given Citius Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Citius Oncology is more favorable than AlloVir.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Oncology
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
AlloVir
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Citius OncologyN/AN/AN/AN/AN/A
AlloVirN/AN/A-$190.42M-$20.23-0.24

Citius Oncology's return on equity of -51.93% beat AlloVir's return on equity.

Company Net Margins Return on Equity Return on Assets
Citius OncologyN/A -51.93% -22.17%
AlloVir N/A -71.03%-61.27%

Citius Oncology has a beta of 2.92, suggesting that its stock price is 192% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.

Summary

Citius Oncology beats AlloVir on 9 of the 10 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALVR vs. The Competition

MetricAlloVirBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$24.01M$352.34M$6.04B$10.51B
Dividend YieldN/AN/A5.73%4.80%
P/E Ratio-0.24N/A84.7027.24
Price / SalesN/A490.63514.31200.41
Price / CashN/A22.4437.5761.53
Price / Book0.163.8112.316.74
Net Income-$190.42M-$133.30M$3.32B$276.59M
7 Day Performance-38.34%-3.97%-1.33%-0.47%
1 Month Performance22.37%14.62%8.13%7.47%
1 Year Performance-73.55%12.15%73.08%34.58%

AlloVir Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALVR
AlloVir
N/A$4.76
+7.0%
N/A-75.8%$24.01MN/A-0.24110High Trading Volume
CTOR
Citius Oncology
3.0376 of 5 stars
$1.91
+2.4%
$6.00
+213.5%
+61.9%$159.84MN/A0.00N/AGap Up
PEPG
PepGen
3.4787 of 5 stars
$4.85
-2.2%
$8.40
+73.2%
-47.6%$159.08MN/A-1.6430
THTX
Theratechnologies
N/A$3.42
+0.9%
N/A+174.3%$157.21M$84.38M-17.99140High Trading Volume
ANRO
Alto Neuroscience
2.5716 of 5 stars
$5.78
-11.7%
$9.80
+69.7%
-59.7%$156.51MN/A-2.42N/A
CGEN
Compugen
1.3601 of 5 stars
$1.74
-3.1%
$4.00
+130.5%
+25.6%$154.83M$27.86M-7.8970News Coverage
CCCC
C4 Therapeutics
3.7595 of 5 stars
$2.18
-4.6%
$8.50
+290.8%
-65.6%$154.80M$35.58M-1.38150
ACOG
Alpha Cognition
2.9475 of 5 stars
$7.40
flat
$20.00
+170.3%
N/A$154.66MN/A-4.63N/A
NVCT
Nuvectis Pharma
3.2461 of 5 stars
$6.06
+0.2%
$15.33
+153.0%
-6.5%$154.29MN/A-5.188
IXHL
Incannex Healthcare
0.8994 of 5 stars
$0.44
-1.0%
N/A-76.8%$153.34M$90K-0.363Gap Down
GLSI
Greenwich LifeSciences
1.2426 of 5 stars
$11.21
-0.7%
$42.00
+274.8%
-23.7%$152.72MN/A-8.243Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ALVR) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners